A RETROSPECTIVE STUDY OF LENGTH OF HOSPITAL STAY IN INFANTS TREATED FOR NEONATAL ABSTINENCE SYNDROME WITH METHADONE VERSUS ORAL MORPHINE PREPARATIONS

2005 ◽  
Vol 5 (5) ◽  
pp. 265-272 ◽  
Author(s):  
Shabnam Lainwala ◽  
Elizabeth R. Brown ◽  
Nancy P. Weinschenk ◽  
Mary T. Blackwell ◽  
James I. Hagadorn
Keyword(s):  
Retrospective Study ◽  
Hospital Stay ◽  
Oral Morphine ◽  
Length Of Hospital Stay ◽  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome

scholarly journals Ineffective morphine treatment regimen for the control of Neonatal Abstinence Syndrome in buprenorphine- and methadone-exposed infants

2012 ◽  
Vol 3 (4) ◽  
pp. 262-270 ◽  
Author(s):  
A. L. Gordon ◽  
O. V. Lopatko ◽  
R. R. Haslam ◽  
H. Stacey ◽  
V. Pearson ◽  
...  
Keyword(s):  
Hospital Stay ◽  
Oral Morphine ◽  
Length Of Hospital Stay ◽  
Maternity Hospital ◽  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome ◽  
Morphine Treatment ◽  
Opioid Agonist ◽  
Control Infant ◽  
Significant Difference

This study aimed to determine if morphine is effective in ameliorating Neonatal Abstinence Syndrome (NAS) symptoms to non-opioid-exposed control levels in methadone- and buprenorphine-exposed infants. A prospective, non-randomized comparison study with flexible dosing was undertaken in a large teaching maternity hospital in Australia. Twenty-five infants in the groups of buprenorphine-, methadone- and control non-opioid-exposed infants were compared (totaln= 75 infants). Oral morphine sulphate (1 mg/ml) was administered every 4 h to opioid agonist-exposed infants. Modified Finnegan Withdrawal Scale (MFWS) scores determined dosing: score of 8–10: 0.5 mg/kg/day, 11–13: 0.7 mg/kg/day and 14+: 0.9 mg/kg/day. Withdrawal score, amount of morphine administered and length of hospital stay, were used to assess NAS over a 4-week follow-up period. No controls achieved a score higher than 7 on the MFWS. There was no significant difference in the percentage of infants requiring treatment between methadone (60%) and buprenorphine (48%) infants. For treated infants, significantly (P< 0.01) more morphine was administered to methadone (40.07 ± 3.95 mg) compared with buprenorphine infants (22.77 ± 4.29 mg) to attempt to control NAS. Following treatment initiation, significantly more (P< 0.01) methadone (87%) compared with buprenorphine infants (42%) continued to exceed scoring thresholds for morphine treatment requirement, and non-opioid-exposed control infant scores. For treated infants, there was no significant difference in length of hospital stay between methadone and buprenorphine infants. Morphine treatment was not entirely effective in ameliorating NAS to non-opioid-exposed control symptom levels in methadone or buprenorphine infants. The regimen may be less effective in methadone compared with buprenorphine infants.

scholarly journals A Retrospective Review Following the Addition of Clonidine to a Neonatal Abstinence Syndrome Treatment Algorithm

2021 ◽  
Vol 9 ◽  
Author(s):  
Mohammad Y. Bader ◽  
Nahla Zaghloul ◽  
Ashley Repholz ◽  
Nadia Nagy ◽  
Mohamed N. Ahmed ◽  
...  
Keyword(s):  
Hospital Stay ◽  
Cumulative Dose ◽  
Medical Center ◽  
Treatment Algorithm ◽  
Length Of Hospital Stay ◽  
Dual Therapy ◽  
Morphine Sulfate ◽  
Neonatal Abstinence Syndrome ◽  
Cumulative Exposure ◽  
Abstinence Syndrome

Objective: To investigate the outcomes associated with the implementation of a neonatal abstinence syndrome (NAS) treatment algorithm utilizing dual therapy with morphine sulfate and clonidine in a level four neonatal intensive care unit (NICU).Study Design: A cohort of neonates (≥35 weeks gestation) born at an academic tertiary medical center between January 1, 2015 and December 31, 2018 who were diagnosed with NAS were retrospectively evaluated following the implementation of a new NAS treatment algorithm. Neonates were categorized in two groups based on if they were treated pre- or post-implementation of the protocol. The primary efficacy outcome was length of hospital stay. Secondary outcomes included the incidence of adverse drug reactions, length of treatment for NAS, and maximum as well as total cumulative dose of each medication used to treat NAS.Results: The implementation of this NAS treatment algorithm significantly reduced the length of hospital stay (30 days vs. 20 days, p = 0.001). In addition, there was a significant decrease in duration of morphine sulfate exposure as well as cumulative dose of morphine required to successfully treat a neonate with NAS in the post-implementation group (26 days vs. 15 days, p = 0.002 and 6.9 mg/kg vs. 3.4 mg/kg, p = 0.031).Conclusion: Addition of clonidine to morphine sulfate as initial therapy for NAS significantly reduced the cumulative exposure as well as duration of exposure to morphine sulfate compared to morphine monotherapy and decrease length of hospital stay.

Effects of Partially Hydrolyzed Formula on Severity and Outcomes of Neonatal Abstinence Syndrome

2019 ◽  
Vol 37 (11) ◽  
pp. 1177-1182 ◽  
Author(s):  
Mahdi Alsaleem ◽  
Sara K. Berkelhamer ◽  
Gregory E. Wilding ◽  
Lorin M. Miller ◽  
Anne Marie Reynolds
Keyword(s):  
Hospital Stay ◽  
Controlled Trial ◽  
Length Of Hospital Stay ◽  
Retrospective Chart Review ◽  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome ◽  
Short Term ◽  
Term Infants ◽  
Near Term ◽  
Hydrolyzed Formula

Abstract Objective This study compares the effect of partially hydrolyzed formula (PHF) and standard formula (SF) on the severity and short-term outcomes of neonatal abstinence syndrome (NAS). Study Design We performed a retrospective chart review of 124 opioid-dependent mothers and their term or near-term infants. Infants were categorized according to the predominant type of formula consumed during the hospital stay. Finnegan's scale was used to assess symptoms of withdrawal. Results A total of 110 infants met our inclusion criteria. Thirty-four (31%) infants were fed predominantly PHF, 60 (54%) infants were fed SF, and 16 (15%) infants were fed maternal breast milk. There was no difference between the infants in the PHF and SF groups with respect to requirement of morphine (MSO4) therapy, maximum dose of MSO4 used, duration of MSO4 treatment or length of hospital stay after performing multivariate analyses to control for type of drug used by the mother, maternal smoking, regular prenatal care, inborn status, and maximum Finnegan score prior to MSO4 treatment. Conclusion Use of PHF failed to impact short-term outcomes in infants treated for NAS including maximum MSO4 dose, duration of MSO4 treatment, and length of hospital stay. A prospective randomized controlled trial may be indicated to confirm this finding.

scholarly journals Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

2018 ◽  
Vol 34 (6) ◽  
pp. 266-272 ◽  
Author(s):  
Bryan M. Bishop
Keyword(s):  
Hospital Stay ◽  
Oral Morphine ◽  
Standard Of Care ◽  
Neonatal Abstinence Syndrome ◽  
Abstinence Syndrome ◽  
Single Center ◽  
Duration Of Treatment ◽  
Current Standard ◽  
Duration Of Hospital Stay ◽  
Oral Methadone

Objective: To summarize the available data for using buprenorphine in neonatal abstinence syndrome and discuss these data in context of the current standard of care therapies, oral morphine and oral methadone. Data Sources: A literature search was conducted using PubMed (1949-May 2018) and EMBASE (1980-May 2018). Combinations of the search terms “buprenorphine,” “neonatal,” and “neonatal abstinence syndrome” were used. Study Selection and Data Extraction: All full-length, English-language studies were included in this review. Data Synthesis: A total of 4 studies were included in this review including 1 retrospective cohort study, 2 prospective single-center open-label randomized trials, and 1 prospective single-center, double-blind study. Oral morphine was the comparator in 3 studies, and oral methadone was the comparator in one. Buprenorphine was associated with a significant reduction in duration of treatment in 3 of the 4 studies and was associated with a significant reduction in duration of hospital stay in 3 of the 4 studies. In the randomized, double-blinded trial, buprenorphine had a significantly reduced duration of treatment (15 vs 28 days, P < .001) and duration of hospital stay (21 vs 33 days, P < .001). The requirement of adjunct treatment was similar between groups in all 4 studies, and buprenorphine did not have any significant adverse reactions in comparison with morphine and methadone. Conclusions: Buprenorphine appears to be a safe option for treating neonatal abstinence syndrome that is potentially superior to the current standard of care therapies with respect to duration of treatment and hospital length of stay.

Sign in / Sign up

Export Citation Format

Share Document